Which funds bought or sold PFE in Q3 2026?
Pfizer Inc. 9 funds bought, 6 sold, out of 109 tracked funds that have filed for Q3 2026. Among active managers, the estimated net flow was −$4M.
Holdings as of Sep 30, 2026 (Q3 2026)13F deadline Nov 16, 2026 (45 days after quarter end)
- AQR+$814M
- Amundi+$382M
- D. E. Shaw+$319M
- Two Sigma+$174M
- ArrowstreetNEW+$106M
- Fisher Investments+$87M
- Man Group+$64M
- RenaissanceNEW+$57M
- MaverickNEW+$3M
- Wellington−$473M
- Goldman Sachs−$262M
- Susquehanna−$166M
- RBC−$84M
- GQGOUT−$3M
- Dodge & Cox−$66K
Top 10 each side. NEW = opened a position, OUT = sold the whole position.
Bought (9)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| AQR Quant & multi-strategy | Added+153.8% | +$814M | $1.3B |
| Amundi Asset manager | Added+40% | +$382M | $1.3B |
| D. E. Shaw Quant & multi-strategy | Added+206.3% | +$319M | $473M |
| Two Sigma Quant & multi-strategy | Added+1843.6% | +$174M | $183M |
| Arrowstreet Quant & multi-strategy | New | +$106M | $106M |
| Fisher Investments Asset manager | Added+2.8% | +$87M | $3.2B |
| Man Group Quant & multi-strategy | Added+246.9% | +$64M | $90M |
| Renaissance Quant & multi-strategy | New | +$57M | $57M |
| Maverick Hedge fund | New | +$3M | $3M |
Sold (6)
| Fund | Change | Est. $ | Now |
|---|---|---|---|
| Wellington Asset manager | Trimmed-59.6% | −$473M | $321M |
| Goldman Sachs Bank & broker | Trimmed-17.3% | −$262M | $1.2B |
| Susquehanna Quant & multi-strategy | Trimmed-89.1% | −$166M | $20M |
| RBC Bank & broker | Trimmed-9% | −$84M | $852M |
| GQG Growth / crossover | Sold out | −$3M | — |
| Dodge & Cox Value investor | Trimmed-2.6% | −$66K | $2M |
Source: SEC EDGAR Form 13F-HR for each fund, holdings as of Sep 30, 2026. Shares only (options excluded). Estimated $ = change in shares × quarter-end price. Funds may have traded since. Methodology. Not investment advice.